Die Story - geht weiter.... - 500 Beiträge pro Seite
eröffnet am 01.09.10 14:25:48 von
neuester Beitrag 21.12.10 12:06:36 von
neuester Beitrag 21.12.10 12:06:36 von
Beiträge: 5
ID: 1.159.657
ID: 1.159.657
Aufrufe heute: 0
Gesamt: 390
Gesamt: 390
Aktive User: 0
ISIN: US2777741057 · WKN: A1CUUH · Symbol: EAPH
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 25.04.24 Nasdaq OTC
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
10,000 | +25,00 | |
6,0000 | +25,00 | |
0,7113 | +21,90 | |
56,69 | +20,00 | |
0,6400 | +18,52 |
Wertpapier | Kurs | Perf. % |
---|---|---|
0,7599 | -15,26 | |
9,7200 | -19,60 | |
4,0000 | -27,27 | |
2,7280 | -29,14 | |
14,510 | -32,32 |
Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team
Lee Hendelson to Join Easton Pharmaceuticals, Public Company Experience Invaluable as New CFO
TORONTO, Aug 30, 2010 (GlobeNewswire via COMTEX) -- Easton Pharmaceuticals (Pink Sheets:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically delivered therapeutic healthcare products, announced today that Lee Hendelson has agreed to join the company as Chief Financial Officer. An Accountant, CFO and Controller for various companies during the past 35 years, Mr. Hendelson will provide direction for all financial matters for Easton Pharmaceuticals in his capacity as Chief Financial Officer.
"As a public company, we are extremely pleased to have someone with Lee's solid experience as CFO," says John Easton, Easton Pharmaceuticals' Chairman of the Board. "He will help guide us through all the necessary regulatory filings and financial issues, and we will also be able to leverage many of Lee's proven skill-sets to move Easton Pharmaceuticals forward to success."
Mr. Hendelson played an integral part in the financial management of, and preparation and filings of financial statements for various publicly traded companies, and worked closely with various venture capital firms in New York City and Palm Beach, Florida analyzing profitability for portfolio clients. Prior to joining Easton Pharmaceuticals, Mr. Hendelson built a successful accounting firm in the United States, providing specialized accounting services, tax problem resolution, tax preparation for businesses and estates, due diligence, forecasting and pro-forma financial statements for business plans. Mr. Hendelson attended The City University of New York and received his Bachelors of Science in Accounting.
About Easton Pharmaceuticals Inc.
Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically delivered therapeutic healthcare products. The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment of FSAD (Female Sexual Arousal Disorder). VIORRA is a topical, daily-use product classified by the FDA as containing Generally Regarded as Safe substances and ingredients. For more information, visit http://www.eastonpharma.com
Copyright (C)2010 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and, the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc. Other names and marks are the property of their respective owners.
This highest-value, lowest cost press release is a service of So Act Network's Press Club. www.pressclub.biz
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Easton Pharmaeuticals
By Staff
CONTACT: CONTACT: Easton Pharmaceuticals Inc.
Media relations:
(416) 619-0291
(347) 284-0192
Fax: +1(888) 877-3723
Media relations:
Media@eastonpharma.com
Investor relations:
IR@eastonpharma.com
info@eastonpharma.com
www.eastonpharma.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
-0-
INDUSTRY KEYWORD: Biotechnology
SUBJECT CODE: PHARMACEUTICALS
MANAGEMENT CHANGES
Directors and Officers
Es gibt noch Einiges mehr:
http://www.otcmarkets.com/stock/EAPH/news
http://www.otcmarkets.com/stock/EAPH/financials
wie z.B.:
Quarterly Report Mar 31, 2010:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
Quarterly Report Jun 30, 2010:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
soviel zu ehem. Lampen, Lampi`s, LAM-Pharmaceuticals, etc.........
!!! Sie und ihr Mythos lebt also doch weiter !!!
stay and keep
http://www.otcmarkets.com/stock/EAPH/news
http://www.otcmarkets.com/stock/EAPH/financials
wie z.B.:
Quarterly Report Mar 31, 2010:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
Quarterly Report Jun 30, 2010:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
soviel zu ehem. Lampen, Lampi`s, LAM-Pharmaceuticals, etc.........
!!! Sie und ihr Mythos lebt also doch weiter !!!
stay and keep
Easton Pharmaceuticals Inc. (EAPH) - Financial and Strategic Analysis Review - new company profile released
Es "bewegt" sich wieder etwas........
http://www.pr-inside.com/easton-pharmaceuticals-inc-eaph-r22…
Es "bewegt" sich wieder etwas........
http://www.pr-inside.com/easton-pharmaceuticals-inc-eaph-r22…
Quarterly Report
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
"Totgesagte" leben länger
also, stay long and keep
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById…
"Totgesagte" leben länger
also, stay long and keep
Easton Pharmaceuticals Announces 2011 "Fast-to-Market" Plan To Introduce Products For Treating Female Sexual Arousal Disorders and Provide Alternative To Ineffective Hormonal Therapies
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+1,61 | |
+0,71 | |
+0,53 | |
+0,88 | |
+1,32 | |
-2,44 | |
+1,52 | |
+0,71 | |
+0,21 | |
+2,56 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
228 | ||
103 | ||
99 | ||
83 | ||
70 | ||
38 | ||
35 | ||
34 | ||
33 | ||
32 |